This document is a patent application (US20260083731A1) published by the USPTO on March 26, 2026. It describes methods of treating uveal melanoma, including ocular tumors, using a PKC inhibitor as a neoadjuvant and/or adjuvant therapy. The stated goals are to reduce the incidence of metastasis and/or enucleation, and to preserve eye function. The application was filed on August 25, 2023, with application number 19106906.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it may signal future patent protection for specific treatments, impacting market exclusivity and research and development strategies for pharmaceutical and medical device companies in the oncology and ophthalmology sectors. Compliance officers should note this as a potential future development in therapeutic treatments.